Albanell J - Search Results

1

Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.

Albanell J, Codony J, Rovira A, Mellado B, Gascón P. Albanell J, et al. Adv Exp Med Biol. 2003;532:253-68. doi: 10.1007/978-1-4615-0081-0_21. Adv Exp Med Biol. 2003. PMID: 12908564 Review.

2

Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis.

Albanell J, Bellmunt J, Molina R, García M, Caragol I, Bermejo B, Ribas A, Carulla J, Gallego OS, Español T, Solé Calvo LA. Albanell J, et al. Anticancer Res. 1996 Mar-Apr;16(2):1027-32. Anticancer Res. 1996. PMID: 8687094

3

Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.

Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Codony-Servat J, et al. Among authors: albanell j. Cancer Res. 1999 Mar 15;59(6):1196-201. Cancer Res. 1999. PMID: 10096547

4

The ErbB receptors as targets for breast cancer therapy.

Albanell J, Baselga J. Albanell J, et al. J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):337-51. doi: 10.1023/a:1018762216147. J Mammary Gland Biol Neoplasia. 1999. PMID: 10705918 Review.

5

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Molina MA, et al. Among authors: albanell j. Cancer Res. 2001 Jun 15;61(12):4744-9. Cancer Res. 2001. PMID: 11406546

6

Mechanism of action of anti-HER2 monoclonal antibodies.

Baselga J, Albanell J. Baselga J, et al. Among authors: albanell j. Ann Oncol. 2001;12 Suppl 1:S35-41. doi: 10.1093/annonc/12.suppl_1.s35. Ann Oncol. 2001. PMID: 11521720 Review.

7

Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.

Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Roselló J, Nicholson RI, Mendelsohn J, Baselga J. Albanell J, et al. Cancer Res. 2001 Sep 1;61(17):6500-10. Cancer Res. 2001. PMID: 11522647

8

Mechanism of action of trastuzumab and scientific update.

Baselga J, Albanell J, Molina MA, Arribas J. Baselga J, et al. Among authors: albanell j. Semin Oncol. 2001 Oct;28(5 Suppl 16):4-11. doi: 10.1016/s0093-7754(01)90276-3. Semin Oncol. 2001. PMID: 11706390 Review.

9

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

Albanell J, Rojo F, Baselga J. Albanell J, et al. Semin Oncol. 2001 Oct;28(5 Suppl 16):56-66. doi: 10.1016/s0093-7754(01)90283-0. Semin Oncol. 2001. PMID: 11706397 Review.

10

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.

Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J. Albanell J, et al. J Clin Oncol. 2002 Jan 1;20(1):110-24. doi: 10.1200/JCO.2002.20.1.110. J Clin Oncol. 2002. PMID: 11773160 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results